Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACLX NASDAQ:AKRO NASDAQ:ARWR NASDAQ:IMTX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$86.99-2.1%$77.12$47.86▼$107.37$4.93B0.31577,642 shs500,598 shsAKROAkero Therapeutics$53.84+0.3%$47.48$21.34▼$58.40$4.29B-0.293.85 million shs1.58 million shsARWRArrowhead Pharmaceuticals$36.81-5.5%$28.68$9.57▼$40.29$5.39B1.132.19 million shs1.88 million shsIMTXImmatics$9.87-3.2%$7.11$3.30▼$11.25$1.24B1.221.14 million shs649,100 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-2.09%+0.22%+13.83%+28.70%-6.46%AKROAkero Therapeutics+0.34%-0.07%+27.64%+3.38%+73.40%ARWRArrowhead Pharmaceuticals-5.54%+3.95%+26.36%+119.63%+74.45%IMTXImmatics-3.24%-4.73%+63.68%+64.50%+4.44%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACLXArcellx$86.99-2.1%$77.12$47.86▼$107.37$4.93B0.31577,642 shs500,598 shsAKROAkero Therapeutics$53.84+0.3%$47.48$21.34▼$58.40$4.29B-0.293.85 million shs1.58 million shsARWRArrowhead Pharmaceuticals$36.81-5.5%$28.68$9.57▼$40.29$5.39B1.132.19 million shs1.88 million shsIMTXImmatics$9.87-3.2%$7.11$3.30▼$11.25$1.24B1.221.14 million shs649,100 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACLXArcellx-2.09%+0.22%+13.83%+28.70%-6.46%AKROAkero Therapeutics+0.34%-0.07%+27.64%+3.38%+73.40%ARWRArrowhead Pharmaceuticals-5.54%+3.95%+26.36%+119.63%+74.45%IMTXImmatics-3.24%-4.73%+63.68%+64.50%+4.44%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACLXArcellx 2.86Moderate Buy$113.0830.00% UpsideAKROAkero Therapeutics 2.31Hold$73.3836.28% UpsideARWRArrowhead Pharmaceuticals 2.78Moderate Buy$43.1417.20% UpsideIMTXImmatics 2.71Moderate Buy$13.6738.47% UpsideCurrent Analyst Ratings BreakdownLatest IMTX, ARWR, ACLX, and AKRO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/16/2025ACLXArcellxStifel NicolausSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetBuy$129.0010/13/2025IMTXImmaticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold10/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/10/2025AKROAkero TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$72.00 ➝ $54.0010/10/2025AKROAkero TherapeuticsWolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Hold10/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$88.0010/9/2025ACLXArcellxCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold$88.0010/9/2025AKROAkero TherapeuticsLifesci CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold10/9/2025AKROAkero TherapeuticsJefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$75.00 ➝ $56.00(Data available from 10/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACLXArcellx$56.98M84.67N/AN/A$8.41 per share10.34AKROAkero TherapeuticsN/AN/AN/AN/A$10.75 per shareN/AARWRArrowhead Pharmaceuticals$572.98M8.88N/AN/A$1.54 per share23.90IMTXImmatics$168.65M7.11$0.24 per share41.75$5.12 per share1.93Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACLXArcellx-$107.35M-$3.42N/AN/AN/A-329.93%-43.04%-27.41%11/6/2025 (Estimated)AKROAkero Therapeutics-$252.06M-$2.00N/AN/AN/AN/A-15.84%-14.59%11/14/2025 (Estimated)ARWRArrowhead Pharmaceuticals-$599.49M-$1.28N/AN/AN/AN/A-40.91%-11.62%11/25/2025 (Estimated)IMTXImmatics$16.47M-$0.65N/AN/AN/A-59.29%-15.60%-12.31%11/17/2025 (Estimated)Latest IMTX, ARWR, ACLX, and AKRO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/14/2025Q3 2025AKROAkero Therapeutics-$0.94N/AN/AN/AN/AN/A11/6/2025Q3 2025ACLXArcellx-$1.00N/AN/AN/A$11.24 millionN/A8/13/2025Q1 2025IMTXImmatics-$0.38-$0.66-$0.28-$0.66$13.05 million$6.48 million8/8/2025Q2 2025AKROAkero Therapeutics-$0.97-$0.86+$0.11-$0.86N/AN/A8/7/2025Q2 2025ACLXArcellx-$1.03-$0.94+$0.09-$0.94$16.76 million$7.55 million8/7/2025Q3 2025ARWRArrowhead Pharmaceuticals-$0.94-$1.26-$0.32-$1.26$29.01 million$27.77 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACLXArcellxN/AN/AN/AN/AN/AAKROAkero TherapeuticsN/AN/AN/AN/AN/AARWRArrowhead PharmaceuticalsN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACLXArcellxN/A3.813.81AKROAkero Therapeutics0.0212.6612.66ARWRArrowhead Pharmaceuticals0.394.874.87IMTXImmaticsN/A8.808.80Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACLXArcellx96.03%AKROAkero TherapeuticsN/AARWRArrowhead Pharmaceuticals62.61%IMTXImmatics64.41%Insider OwnershipCompanyInsider OwnershipACLXArcellx8.35%AKROAkero Therapeutics7.07%ARWRArrowhead Pharmaceuticals4.30%IMTXImmatics3.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACLXArcellx8055.46 million50.83 millionOptionableAKROAkero Therapeutics3079.99 million74.33 millionOptionableARWRArrowhead Pharmaceuticals400138.26 million132.31 millionOptionableIMTXImmatics260121.55 million117.54 millionOptionableIMTX, ARWR, ACLX, and AKRO HeadlinesRecent News About These CompaniesBrokers Set Expectations for Immatics FY2025 Earnings2 hours ago | americanbankingnews.comImmatics (NASDAQ:IMTX) Reaches New 1-Year High - Time to Buy?October 17 at 10:59 AM | marketbeat.comChardan Capital Weighs in on Immatics FY2026 EarningsOctober 17 at 2:59 AM | americanbankingnews.comAnalysts Offer Predictions for Immatics FY2025 EarningsOctober 16 at 7:33 AM | marketbeat.comBrokers Set Expectations for Immatics FY2026 EarningsOctober 15 at 7:51 AM | marketbeat.comImmatics (NASDAQ:IMTX) Stock Rating Upgraded by Zacks ResearchOctober 15 at 7:36 AM | marketbeat.comImmatics (NASDAQ:IMTX) Reaches New 1-Year High - Here's What HappenedOctober 10, 2025 | marketbeat.comImmatics: Multiple Clinical Catalysts In Q4 '25 And 2026October 10, 2025 | seekingalpha.comImmatics' (IMTX) Sell (D-) Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comImmatics Appoints Venkat Ramanan as Chief Financial OfficerOctober 1, 2025 | finance.yahoo.comImmatics N.V. Appoints Venkat Ramanan, Ph.D. as Chief Financial OfficerOctober 1, 2025 | quiverquant.comQImmatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of "Moderate Buy" from AnalystsSeptember 30, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Trading Up 6.7% - Still a Buy?September 26, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Shares Up 8.8% - Still a Buy?September 19, 2025 | marketbeat.comImmatics (NASDAQ:IMTX) Now Covered by GuggenheimSeptember 19, 2025 | marketbeat.comGuggenheim Initiates Coverage of Immatics N.V. (IMTX) with Buy RecommendationSeptember 19, 2025 | msn.comImmatics initiated with a Buy at GuggenheimSeptember 17, 2025 | msn.comImmatics N.V. Reports Q2 2025 Financial ResultsAugust 20, 2025 | msn.comNew Strong Sell Stocks for August 15thAugust 18, 2025 | zacks.comImmatics N.V. (NASDAQ:IMTX) Analysts Just Slashed This Year's EstimatesAugust 18, 2025 | finance.yahoo.comLeerink Partners Reaffirms Their Buy Rating on Immatics (IMTX)August 17, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMTX, ARWR, ACLX, and AKRO Company DescriptionsArcellx NASDAQ:ACLX$86.99 -1.86 (-2.09%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$86.94 -0.05 (-0.06%) As of 10/17/2025 04:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcellx, Inc., together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company's lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM). It also develops ACLX-001, a product candidate in Phase 1 clinical trials targeting BCMA to treat rrMM; and ACLX-002, which is in Phase 1 clinical trials that targets CD123 for treating relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). In addition, the company's preclinical product includes ACLX-003 for the treatment of AML and MDS. Further, it focuses on the development of product candidates for solid tumor programs. It has a strategic alliance with Kite Pharma, Inc. to co-develop and co-commercialize anitocabtagene autoleucel. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.Akero Therapeutics NASDAQ:AKRO$53.84 +0.18 (+0.34%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$53.87 +0.03 (+0.06%) As of 10/17/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Akero Therapeutics, Inc., together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients. It has a license agreement with Amgen Inc. to develop, manufacture, use, distribute, and sell EFX as a treatment for MASH and other metabolic diseases. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.Arrowhead Pharmaceuticals NASDAQ:ARWR$36.81 -2.16 (-5.54%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$37.27 +0.46 (+1.25%) As of 10/17/2025 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.Immatics NASDAQ:IMTX$9.87 -0.33 (-3.24%) Closing price 10/17/2025 04:00 PM EasternExtended Trading$9.86 -0.01 (-0.15%) As of 10/17/2025 06:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Institutions Are Fueling CrowdStrike’s Next Leg Higher This AI Chip Giant Could Be the Market’s Next Big Winner Microsoft & NVIDIA Unveil GB300 Supercomputer as AI Race Heats Up This Less-Hyped Tech Stock Could Be the Key to the Next AI Wave Archer Buys Rival's Patent Treasure Trove in Strategic Move Prologis Stock Surges: Why the Rally May Continue Intel's Turnaround Hits Hyperspeed With A New 52-Week High Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
